Abstract
Ulcerative colitis (UC) negatively affects health-related quality of life (HRQoL), but on this topic are scarce. The objective of the current study is to determine the HRQoL in UC patients treated with tofacitinib in randomized controlled trials (RCTs).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
